Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 300

Sort by

Sort Order Select

Journal Articles

AMG 701 Potently Induces Anti-Multiple Myeloma (MM) Functions of T Cells and IMiDs Further Enhance Its Efficacy to Prevent MM Relapse In Vivo

Shih-Feng Cho, MD PhD, Liang Lin, PhD, Lijie Xing, MD, Kenneth Wen, Tengteng Yu, MD PhD, Phillip A Hsieh, Yuyin Li, PhD, Nikhil C. Munshi, MD, Joachim Wahl, PhD, Katja Matthes, Kenneth C. Anderson, MD, Tara Chapman-Arvedson, Yu-Tzu Tai, PhD

Blood (2019) 134 (Supplement_1): 135.

https://doi.org/10.1182/blood-2019-128528

Published: 2019

Journal Articles

Mapping MALT1 Signaling Connectivity Unveils Novel B-Cell Feedback Mechanisms Directing Assembly of Potent Anti-Lymphoma Regimens

Lorena Fontan, PhD, Matthew Durant, Rebecca Goldstein, PhD, Matthew R Teater, PhD, Gabriella Casalena, PhD, Min Xia, PhD, Jimmy Wilson, Ilkay Us, Giorgio Inghirami, MD, Ari Melnick, MD

Blood (2019) 134 (Supplement_1): 173.

https://doi.org/10.1182/blood-2019-130516

Published: 2019

Journal Articles

First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial

Luciano J. Costa, MD PhD, Sandy W. Wong, Arancha Bermúdez, Javier de la Rubia, María-Victoria Mateos, Enrique M. Ocio, Paula Rodríguez-Otero, Jesús San-Miguel, Shaoyi Li, Rafael Sarmiento, Pilar Lardelli, Allison Gaudy, Isaac Boss, Lisa M. Kelly, Michael R. Burgess, Kristen Hege, William I. Bensinger

Blood (2019) 134 (Supplement_1): 143.

https://doi.org/10.1182/blood-2019-122895

Published: 2019

Journal Articles

DT2216, a BCL-XL Proteolysis Targeting Chimera (PROTAC), Is a Potent Anti T-Cell Lymphoma Agent That Does Not Induce Significant Thrombocytopenia

Yonghan He, MD, Raphael Koch, Vivekananda Budamagunta, Dongwen Lv, Sajid Khan, Xuan Zhang, Janet S Wiegand, Guangrong Zheng, David M. Weinstock, MD, Daohong Zhou

Blood (2019) 134 (Supplement_1): 303.

https://doi.org/10.1182/blood-2019-125820

Published: 2019

Journal Articles

Clinical Significance of KIR Genotype in Patients with Methotrexate-Associated Lymphoproliferative Disorders

Norina Tanaka, MD PhD, Aya Watanabe, MD, Suguru Honda, MD, Mitsuko Kobayashi, Yan-Hua Wang, MD, Yuki Iizuka, MD, Michiko Ryuzaki, MD, Midori Ishiyama, MD PhD, Akihito Shinohara, MD PhD, Hiroshi Kazama, MD PhD, Shotaro Hagiwara, MD PhD, Kentaro Yoshinaga, MD PhD, Katsunori Ikari, MD PhD, Masayuki Shiseki, MD PhD, Masayoshi Harigai, MD PhD, Junji Tanaka, MD PhD

Blood (2019) 134 (Supplement_1): 5219.

https://doi.org/10.1182/blood-2019-127836

Published: 2019

Journal Articles

Initial Characterization and Toxicology of an Nmt Inhibitor in Development for Hematologic Malignancies

Michael Weickert, John Dillberger, John R. Mackey, Paul Wyatt, David Gray, Kevin Read, Christian Li, Audrey Parenteau, Luc G. Berthiaume

Blood (2019) 134 (Supplement_1): 3362.

https://doi.org/10.1182/blood-2019-124934

Published: 2019

Journal Articles

Reprogramming Leukemia Cells into Antigen Presenting Cells As a Novel Cancer Vaccination Immunotherapy

Miles Hamilton Linde, BS, BA, Christopher G Dove, Sarah F Gurev, Paul Phan, Feifei Zhao, MD, Lindsay P Miller, Ravindra Majeti, MD PhD

Blood (2019) 134 (Supplement_1): 3217.

https://doi.org/10.1182/blood-2019-128577

Published: 2019

Journal Articles

An Open-Label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477, a First in Clinic Inhibitor of the p300/CPB Bromodomains, As Monotherapy in Patients with Advanced Haematological Malignancies

Tomasz Knurowski, PhD MD, Karen Clegg, PhD, Nigel Brooks, PhD, Fay Ashby, Neil A Pegg, PhD, William West, PhD, Harriet S Walter, Tim CP Somervaille, MD PhD, Steven Knapper, DM, Andrew Davies, MD PhD

Blood (2019) 134 (Supplement_1): 1266.

https://doi.org/10.1182/blood-2019-124797

Published: 2019

Journal Articles

SM09419, a Novel, Small-Molecule CDC-like Kinase (CLK) Inhibitor, Demonstrates Strong Inhibition of the Wnt Signaling Pathway and Antitumor Effects in Mantle Cell Lymphoma Models

Heekyung Chung, PhD, Emily Creger, Lauren Sitts, Kevin Chiu, Chi-Ching Mak, PhD, Sunil KC, PhD, Betty Tam, PhD, Gail Bucci, Josh Stewart, Timothy Phalen, PhD, Steven Cha, MD

Blood (2019) 134 (Supplement_1): 4059.

https://doi.org/10.1182/blood-2019-124812

Published: 2019

Journal Articles

Vls-101 Is a Novel Therapeutic Antibody-Drug Conjugate (ADC) Targeting Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Richter's Syndrome (RS)

Tiziana Vaisitti, PhD, Katti Jessen, PhD, Thanh-Trang Vo, PhD, Mira Ko, Francesca Arruga, PhD, Nicoletta Vitale, PhD, Esteban Braggio, PhD, Arianna Di Napoli, Amy Chadburn, MD, John N. Allan, MD, Richard R. Furman, MD, Langdon L. Miller, Brian J Lanutti, PhD, Silvia Deaglio, MD PhD

Blood (2019) 134 (Supplement_1): 2856.

https://doi.org/10.1182/blood-2019-126827

Published: 2019

Journal Articles

The Dual PI3K-δ/γ Inhibitor Duvelisib in Combination with the Bcl-2 Inhibitor Venetoclax Shows Promising Responses in Richter Syndrome-PDX Models

Andrea Iannello, PhD, Francesca Arruga, PhD, Nicoletta Vitale, PhD, Elisa Marchi, Richard R. Furman, MD, John N. Allan, MD, Silvia Coma, PhD, Jonathan A. Pachter, PhD, Silvia Deaglio, MD PhD, Tiziana Vaisitti, PhD

Blood (2019) 134 (Supplement_1): 2862.

https://doi.org/10.1182/blood-2019-125754

Published: 2019

Journal Articles

SM09419, a Novel, Small-Molecule CDC-like Kinase (CLK) Inhibitor, Demonstrates Strong Inhibition of the Wnt Signaling Pathway and Antitumor Effects in Tumor Protein p53 (TP53)-Mutant Acute Myeloid Leukemia Models

Heekyung Chung, PhD, Emily Creger, Lauren Sitts, Kevin Chiu, Chi-Ching Mak, PhD, Sunil KC, PhD, Betty Tam, PhD, Gail Bucci, Josh Stewart, Timothy Phalen, PhD, Steven Cha, MD

Blood (2019) 134 (Supplement_1): 3913.

https://doi.org/10.1182/blood-2019-131209

Published: 2019

Journal Articles

Overcoming CD19 Antigen Loss in B-Cell Malignancies with CAR T Cells Targeting BAFF-R

Hong Qin, MD PhD, Zhenyuan Dong, PhD, Xiuli Wang, PhD, Wesley Cheng, BS, Diane Lynne Smith, PhD, Joo Y Song, MD, Ibrahim Aldoss, MD, Stephen J Forman, MD, Larry W Kwak, MD PhD

Blood (2019) 134 (Supplement_1): 3871.

https://doi.org/10.1182/blood-2019-129228

Published: 2019

Journal Articles

A Phase Ib/II Study of the Histone Methyltransferase Inhibitor Pinometostat in Combination with Azacitidine in Patients with 11q23-Rearranged Acute Myeloid Leukemia

Kamal Menghrajani, MD, Sheng F Cai, MD PhD, Sean M. Devlin, PhD, Scott A. Armstrong, MD PhD, Richard Piekarz, MD PhD MS, BA, Michelle Rudek, PharmD, PhD, Martin S. Tallman, MD, Eytan M. Stein, MD

Blood (2019) 134 (Supplement_1): 2655.

https://doi.org/10.1182/blood-2019-121926

Published: 2019

Journal Articles

A Combination Therapy with Dendritic Cells, Pomalidomide and Programmed Death-Ligand 1 Blockade Exerts a Potent Antitumor Immunity in a Murine Model of Multiple Myeloma

Je-Jung Lee, MD PhD, Tan-Huy Chu, Manh-Cuong Vo, Hye-Sung Park, Thangaraj Jaya Lakshmi, Seo-Yeon Ahn, MD, Ga-Young Song, Sung-Hoon Jung, MD, Hyeoung-Joon Kim, MD PhD

Blood (2019) 134 (Supplement_1): 1819.

https://doi.org/10.1182/blood-2019-127964

Published: 2019

Journal Articles

CC-92480, a Novel Cereblon E3 Ligase Modulator, Is Synergistic with Dexamethasone, Bortezomib, and Daratumumab in Multiple Myeloma

Lilly Wong, Rama Krishna Narla, Jim Leisten, Daniel Bauer, Matthew Groza, Bonny Gaffney, Courtney G. Havens, Justin Choi, Jack Houston, Antonia Lopez-Girona, Joshua Hansen, Brian E. Cathers, James Carmichael, Daniel W. Pierce

Blood (2019) 134 (Supplement_1): 1815.

https://doi.org/10.1182/blood-2019-124345

Published: 2019

Journal Articles

Highly Differentiated Anti-CD47 Antibody, AO-176, Potently Inhibits Hematologic Malignancies Alone and in Combination

John Richards, PhD, Myriam N Bouchlaka, BS,PhD, Robyn J Puro, PhD, Ben J Capoccia, PhD, Ronald R Hiebsch, BS, Michael J Donio, BS, W. Casey Wilson, PhD, Prabir Chakraborty, PhD, Victoria Sung, PhD, Daniel S Pereira, PhD

Blood (2019) 134 (Supplement_1): 1844.

https://doi.org/10.1182/blood-2019-126298

Published: 2019

Journal Articles

Long-Term T Cell Expansion Results in Increased Numbers of Central Memory T Cells with Sustained Functional Properties for Adoptive T Cell Therapy

Stefanie Herda, PhD, Andreas Heimann, MSc, Stefanie Althoff, MSc, Josefine Ruß, Lars Bullinger, Dieter Beule, PhD, Benedikt Obermayer, PhD, Il-Kang Na, MD

Blood (2019) 134 (Supplement_1): 1943.

https://doi.org/10.1182/blood-2019-124736

Published: 2019

Journal Articles

MYC Oncogene Abrogates Natural Killer (NK) Cell-Mediated Immune Surveillance of B- and T- Lymphoid Malignancies By Suppressing STAT1/2-Type I IFN Signaling

Srividya Swaminathan, PhD, Line Dam Heftdal, MD, Daniel Liefwalker, PhD, Renumathy Dhanasekaran, MD, Anja Deutzmann, PhD, Crista Horton, BS, Adriane Mosley, BS, Mariola Liebersbach, BS, Andrew Gentles, PhD, Holden T. Maecker, PhD, Dean Felsher, MD PhD

Blood (2019) 134 (Supplement_1): 730.

https://doi.org/10.1182/blood-2019-122607

Published: 2019

Journal Articles

iPSC-Derived NK Cells Synergize with T Cells and Anti-PD-1 Antibody to Mediate Durable Anti-Tumor Responses In Vivo

Jeffrey S. Miller, MD, Ryan Bjordahl, PhD, Svetlana Gaidarova, MS, Sajid Mahmood, PhD, Paul Rogers, PhD, Ge Moyar, Bruce R. Blazar, MD, Dan S Kaufman, MD PhD, Bahram Valamehr, PhD, Frank Cichocki, PhD

Blood (2019) 134 (Supplement_1): 1933.

https://doi.org/10.1182/blood-2019-124961

Published: 2019

NARROW

AMG 701 Potently Induces Anti-Multiple Myeloma (MM) Functions of T Cells and IMiDs Further Enhance Its Efficacy to Prevent MM Relapse In Vivo

Mapping MALT1 Signaling Connectivity Unveils Novel B-Cell Feedback Mechanisms Directing Assembly of Potent Anti-Lymphoma Regimens

First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial

DT2216, a BCL-XL Proteolysis Targeting Chimera (PROTAC), Is a Potent Anti T-Cell Lymphoma Agent That Does Not Induce Significant Thrombocytopenia

Clinical Significance of KIR Genotype in Patients with Methotrexate-Associated Lymphoproliferative Disorders

Initial Characterization and Toxicology of an Nmt Inhibitor in Development for Hematologic Malignancies

Reprogramming Leukemia Cells into Antigen Presenting Cells As a Novel Cancer Vaccination Immunotherapy

An Open-Label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477, a First in Clinic Inhibitor of the p300/CPB Bromodomains, As Monotherapy in Patients with Advanced Haematological Malignancies

SM09419, a Novel, Small-Molecule CDC-like Kinase (CLK) Inhibitor, Demonstrates Strong Inhibition of the Wnt Signaling Pathway and Antitumor Effects in Mantle Cell Lymphoma Models

Vls-101 Is a Novel Therapeutic Antibody-Drug Conjugate (ADC) Targeting Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Richter's Syndrome (RS)

The Dual PI3K-δ/γ Inhibitor Duvelisib in Combination with the Bcl-2 Inhibitor Venetoclax Shows Promising Responses in Richter Syndrome-PDX Models

SM09419, a Novel, Small-Molecule CDC-like Kinase (CLK) Inhibitor, Demonstrates Strong Inhibition of the Wnt Signaling Pathway and Antitumor Effects in Tumor Protein p53 (TP53)-Mutant Acute Myeloid Leukemia Models

Overcoming CD19 Antigen Loss in B-Cell Malignancies with CAR T Cells Targeting BAFF-R

A Phase Ib/II Study of the Histone Methyltransferase Inhibitor Pinometostat in Combination with Azacitidine in Patients with 11q23-Rearranged Acute Myeloid Leukemia

A Combination Therapy with Dendritic Cells, Pomalidomide and Programmed Death-Ligand 1 Blockade Exerts a Potent Antitumor Immunity in a Murine Model of Multiple Myeloma

CC-92480, a Novel Cereblon E3 Ligase Modulator, Is Synergistic with Dexamethasone, Bortezomib, and Daratumumab in Multiple Myeloma

Highly Differentiated Anti-CD47 Antibody, AO-176, Potently Inhibits Hematologic Malignancies Alone and in Combination

Long-Term T Cell Expansion Results in Increased Numbers of Central Memory T Cells with Sustained Functional Properties for Adoptive T Cell Therapy

MYC Oncogene Abrogates Natural Killer (NK) Cell-Mediated Immune Surveillance of B- and T- Lymphoid Malignancies By Suppressing STAT1/2-Type I IFN Signaling

iPSC-Derived NK Cells Synergize with T Cells and Anti-PD-1 Antibody to Mediate Durable Anti-Tumor Responses In Vivo

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only